This article provides an overview of the dermatology pipeline, reviewing medications for alopecia areata, atopic dermatitis, and plaque psoriasis, with a focus on JAK inhibitors for alopecia areata. Recent atopic dermatitis approvals include abrocitinib, upadacitinib, dupilumab, and tralokinumab, with lebrikizumab in phase 3 research. Promising plaque psoriasis treatments include deucravacitinib, bimekizumab, and various other options, including gene therapy.

Reference: Biscaldi L. Dermatology Pipeline Updates: Plaque Psoriasis, Atopic Dermatitis and More. Dermatology Times. Published June 14, 2023. Accessed December 28, 2023. https://www.dermatologytimes.com/view/dermatology-pipeline-updates-plaque-psoriasis-atopic-dermatitis-and-more